about
Osteocyte-Secreted Wnt Signaling Inhibitor Sclerostin Contributes to Beige Adipogenesis in Peripheral Fat Depots.Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levelsEffects of Age and Estrogen on Skeletal Gene Expression in Humans as Assessed by RNA Sequencing.Sclerostin serum levels in patients with systemic autoimmune diseasesBone and Mineral Metabolism: Where Are We, Where Are We Going, and How Will We Get There?Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patientsSclerostin does not play a major role in the pathogenesis of skeletal complications in type 2 diabetes mellitusVitamin D and spondyloarthritis.Role and mechanism of action of sclerostin in bone.Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts.Hormonal and systemic regulation of sclerostin.Ischemic heart disease is associated with lower cortical volumetric bone mineral density of distal radius.The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study.TIEG and estrogen modulate SOST expression in the murine skeleton.Bone Turnover Markers After Sleep Restriction and Circadian Disruption: A Mechanism for Sleep-Related Bone Loss in Humans.24-hour profile of serum sclerostin and its association with bone biomarkers in men.Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study.Canalization Leads to Similar Whole Bone Mechanical Function at Maturity in Two Inbred Strains of Mice.Validation of a novel, rapid, high precision sclerostin assay not confounded by sclerostin fragments.Muscle-Bone Crosstalk: Emerging Opportunities for Novel Therapeutic Approaches to Treat Musculoskeletal Pathologies.Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis.
P2860
Q33925973-536A7CA5-104D-4A44-A755-4682B5AABE2FQ34661015-2774E1FE-B23E-45BF-A48D-417F95ED5274Q35786468-0134C207-EFC2-454E-938C-14F4ED44BD2EQ36561360-3C446946-2A37-4B20-9B51-7BA4335D07B8Q36716016-C5438A3F-15DD-4129-BF56-BBE58747B484Q36793394-0C9C76F1-8843-4B71-8B7E-745AEAD3E038Q37549113-65C218DD-FCEC-4EAB-B471-67FE13021915Q38262855-D5D62311-096E-4811-A829-F790F86DF504Q38807230-3782323D-0BD1-4299-9EEF-F46FD342C955Q38972516-4F7C88BE-096A-43E4-9D22-762256C15A69Q39037907-91AD78CD-CB9F-412A-ACA3-960FD7CFECDFQ41023046-18854F9F-AF6E-401F-8734-7DEEF955118CQ45875322-E4AFA6C2-3920-4597-8613-8968179A208DQ47606161-C04AAFC0-8092-4452-A6FF-7F46AC7AA1CBQ47668375-3ED74798-4803-4151-BBA3-1B69C7B29D7EQ47704837-F23BBBDC-A22A-41B9-84E3-24E87213ED5EQ48762542-C38AA257-15FA-4B84-8629-8400A830F0E2Q50456863-CE2A5D4C-6076-47EF-997B-D8DCDB260064Q51762210-DE5EA665-3A29-4DA1-9301-5EED55577BCFQ53005827-C1BFCF28-1F11-47C6-A3DC-02EBFB2A82A3Q53137198-91203462-136B-4BF0-8951-A8AE49319124
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical utility of serum sclerostin measurements.
@en
Clinical utility of serum sclerostin measurements.
@nl
type
label
Clinical utility of serum sclerostin measurements.
@en
Clinical utility of serum sclerostin measurements.
@nl
prefLabel
Clinical utility of serum sclerostin measurements.
@en
Clinical utility of serum sclerostin measurements.
@nl
P2860
P356
P1433
P1476
Clinical utility of serum sclerostin measurements.
@en
P2093
Bart L Clarke
Matthew T Drake
P2860
P2888
P356
10.1038/BONEKEY.2013.95
P577
2013-06-05T00:00:00Z
P5875
P6179
1006564935